Weighted Average Number of Shares Outstanding, Basic of BIOMARIN PHARMACEUTICAL INC from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
BIOMARIN PHARMACEUTICAL INC quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • BIOMARIN PHARMACEUTICAL INC Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 191,787,000, a 0.93% increase year-over-year.
  • BIOMARIN PHARMACEUTICAL INC annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 191,787,000, a 0.93% increase from 2024.
  • BIOMARIN PHARMACEUTICAL INC annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 190,027,000, a 1.2% increase from 2023.
  • BIOMARIN PHARMACEUTICAL INC annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 187,834,000, a 1.4% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

BIOMARIN PHARMACEUTICAL INC Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 191,787,000 +1,760,000 +0.93% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 192,032,000 +1,603,000 +0.84% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 191,907,000 +1,793,000 +0.94% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 190,967,000 +2,101,000 +1.1% 01 Jan 2025 31 Mar 2025 10-Q 02 May 2025 2025 Q1
Q4 2024 190,027,000 +2,193,000 +1.2% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 190,429,000 +2,210,000 +1.2% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 190,114,000 +2,166,000 +1.2% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 188,866,000 +2,199,000 +1.2% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2025 2025 Q1
Q4 2023 187,834,000 +2,568,000 +1.4% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 188,219,000 +2,622,000 +1.4% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 187,948,000 +2,694,000 +1.5% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 186,667,000 +2,677,000 +1.5% 01 Jan 2023 31 Mar 2023 10-Q 26 Apr 2024 2024 Q1
Q4 2022 185,266,000 +2,414,000 +1.3% 01 Oct 2022 31 Dec 2022 10-K 24 Feb 2025 2024 FY
Q3 2022 185,597,000 +2,383,000 +1.3% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 185,254,000 +2,410,000 +1.3% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 183,990,000 +2,218,000 +1.2% 01 Jan 2022 31 Mar 2022 10-Q 28 Apr 2023 2023 Q1
Q4 2021 182,852,000 +2,048,000 +1.1% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 183,214,000 +2,072,000 +1.1% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 182,844,000 +2,115,000 +1.2% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 181,772,000 +1,874,000 +1% 01 Jan 2021 31 Mar 2021 10-Q 29 Apr 2022 2022 Q1
Q4 2020 180,804,000 +1,765,000 +0.99% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
Q3 2020 181,142,000 +1,853,000 +1% 01 Jul 2020 30 Sep 2020 10-Q 29 Oct 2021 2021 Q3
Q2 2020 180,729,000 +1,681,000 +0.94% 01 Apr 2020 30 Jun 2020 10-Q 30 Jul 2021 2021 Q2
Q1 2020 179,898,000 +1,627,000 +0.91% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 179,039,000 +1,978,000 +1.1% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
Q3 2019 179,289,000 +1,808,000 +1% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 179,048,000 +2,175,000 +1.2% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 178,271,000 +2,339,000 +1.3% 01 Jan 2019 31 Mar 2019 10-Q 01 May 2020 2020 Q1
Q4 2018 177,061,000 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 177,481,000 +2,378,000 +1.4% 01 Jul 2018 30 Sep 2018 10-Q/A 04 Nov 2019 2019 Q3
Q2 2018 176,873,000 01 Apr 2018 30 Jun 2018 10-Q 02 Aug 2019 2019 Q2
Q1 2018 175,932,000 +3,222,000 +1.9% 01 Jan 2018 31 Mar 2018 10-Q 29 Apr 2019 2019 Q1
Q3 2017 175,103,000 +7,389,000 +4.4% 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2017 2017 Q3
Q1 2017 172,710,000 01 Jan 2017 31 Mar 2017 10-Q 27 Apr 2018 2018 Q1
Q3 2016 167,714,000 +6,828,000 +4.2% 01 Jul 2016 30 Sep 2016 10-Q 31 Oct 2017 2017 Q3
Q4 2015 160,025,000 +13,676,000 +9.3% 01 Oct 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
Q3 2015 160,886,000 +13,870,000 +9.4% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 160,406,000 +14,286,000 +9.8% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2015 2015 Q2
Q1 2015 157,612,000 +13,629,000 +9.5% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2015 2015 Q1
Q4 2014 146,349,000 01 Oct 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
Q3 2014 147,016,000 +6,220,000 +4.4% 01 Jul 2014 30 Sep 2014 10-Q 02 Nov 2015 2015 Q3
Q2 2014 146,120,000 +6,720,000 +4.8% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 143,983,000 +16,014,000 +13% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q3 2013 140,796,000 01 Jul 2013 30 Sep 2013 10-Q 28 Oct 2014 2014 Q3
Q2 2013 139,400,000 +21,488,000 +18% 01 Apr 2013 30 Jun 2013 10-Q 31 Jul 2014 2014 Q2
Q1 2013 127,969,000 +12,899,000 +11% 01 Jan 2013 31 Mar 2013 10-Q 02 May 2014 2014 Q1
Q2 2012 117,912,000 +6,798,000 +6.1% 01 Apr 2012 30 Jun 2012 10-Q 29 Jul 2013 2013 Q2
Q1 2012 115,070,000 +4,418,000 +4% 01 Jan 2012 31 Mar 2012 10-Q 30 Apr 2012 2012 Q1
Q4 2011 112,122,000 +9,029,000 +8.8% 01 Oct 2011 31 Dec 2011 10-K 26 Feb 2013 2012 FY
Q3 2011 112,290,000 +10,180,000 +10% 01 Jul 2011 30 Sep 2011 10-Q 31 Oct 2011 2011 Q3
Q2 2011 111,114,000 +9,402,000 +9.2% 01 Apr 2011 30 Jun 2011 10-Q 01 Aug 2011 2011 Q2
Q1 2011 110,652,000 +9,508,000 +9.4% 01 Jan 2011 31 Mar 2011 10-Q 30 Apr 2012 2012 Q1
Q4 2010 103,093,000 01 Oct 2010 31 Dec 2010 10-K 26 Feb 2013 2012 FY
Q3 2010 102,110,000 01 Jul 2010 30 Sep 2010 10-Q 31 Oct 2011 2011 Q3
Q2 2010 101,712,000 01 Apr 2010 30 Jun 2010 10-Q 01 Aug 2011 2011 Q2
Q1 2010 101,144,000 01 Jan 2010 31 Mar 2010 10-Q 29 Apr 2011 2011 Q1

BIOMARIN PHARMACEUTICAL INC Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 191,787,000 +1,760,000 +0.93% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 190,027,000 +2,193,000 +1.2% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 187,834,000 +2,568,000 +1.4% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 185,266,000 +2,414,000 +1.3% 01 Jan 2022 31 Dec 2022 10-K 24 Feb 2025 2024 FY
2021 182,852,000 +2,048,000 +1.1% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 180,804,000 +1,765,000 +0.99% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 179,039,000 +1,978,000 +1.1% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
2018 177,061,000 +2,634,000 +1.5% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 174,427,000 +8,442,000 +5.1% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 165,985,000 +5,960,000 +3.7% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 160,025,000 +13,676,000 +9.3% 01 Jan 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
2014 146,349,000 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
2012 120,271,000 +8,149,000 +7.3% 01 Jan 2012 31 Dec 2012 10-K 26 Feb 2013 2012 FY
2011 112,122,000 +9,029,000 +8.8% 01 Jan 2011 31 Dec 2011 10-K 26 Feb 2013 2012 FY
2010 103,093,000 01 Jan 2010 31 Dec 2010 10-K 26 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.